Hypomethylating Agents Use in Acute Myeloid Leukemia: A Single-Center Experience

Abstract Context: Acute myeloid leukemia (AML) is a heterogeneous disease. Approximately 80% of older AML patients will die of their disease or its treatment with currently available antileukemic therapy because of the adverse prognostic risk factors. In elderly patients who are not candidates for i...

Full description

Saved in:
Bibliographic Details
Published in:Indian journal of medical and paediatric oncology 2020-03, Vol.41 (2), p.202-208
Main Authors: Bodepudi, Sravan Kumar, Devdas, Santhosh Kumar, Maka, Vinayak V, Rasmi, Palassery, Hiregoudar, Sumathi S, Kilara, Nalini
Format: Article
Language:English
Subjects:
Acute myelocytic leukemia
Age
Care and treatment
Chemotherapy
Comorbidity
Computer industry
Cytogenetics
Decitabine
Deoxyribonucleic acid
DNA
DNA methylation
Epigenetics
Gene expression
Genomes
Leukemia
Original Article
Patients
Response rates
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Context: Acute myeloid leukemia (AML) is a heterogeneous disease. Approximately 80% of older AML patients will die of their disease or its treatment with currently available antileukemic therapy because of the adverse prognostic risk factors. In elderly patients who are not candidates for induction chemotherapy (IC) or who declines IC, the preferred induction regimen is with hypomethylating agents (HMAs). In India, data regarding therapy with HMA, response to therapy and overall survival (OS) is seldom reported. Aims: This study aims to study the response rate and survival of patients treated with HMAs in whom IC was not feasible. Settings and Design: This is retrospective and descriptive single-center study. Subjects and Methods: Data of newly diagnosed AML patients who were unfit for IC and treated with HMA in our institution was collected retrospectively and analyzed. Results: Twenty-three patients received HMAs as a treatment for AML. Eight (34.7%) of 23 patients had initial response to therapy (two [25%] had complete remission [CR], four [50%] had CR with incomplete hematologic recovery, one [12.5%] had partial remission) and one (12.5%) had stable disease. The median progression-free survival and OS observed are 6.06 ± 0.65 months and 7 ± 1.32 months, respectively. Conclusions: HMAs provide an important additional treatment option in newly diagnosed AML patients who are older, with poor performance status, higher comorbidity indices, and who refuse IC.
ISSN:0971-5851
0975-2129
DOI:10.4103/ijmpo.ijmpo_155_19